CHORD Therapeutics Sàrl

Chord Therapeutics is a clinical-stage pharmaceutical company developing drugs for patients with rare, life-threatening, and severely disabling diseases. We are advancing our lead drug candidate CRD1 under orphan drug designation for the treatment of Neuromyelitis Optica (NMO) and Myasthenia Gravis (MG).

At Chord Therapeutics, we are dedicated to changing the lives of patients affected by rare diseases that often have no or only limited treatment options.

We build our development programs on well-understood active substances with a history of clinical testing and use in human patients. We carefully select new indications based on a strong scientific rationale for a benefit of the mode of action of the drug in the selected disease. Taking a molecule with well studied safety and pharmacology forward to a new indication significantly reduces risk for patients and increases the likelihood for a successful development bringing new treatment options to patients and healthcare providers.

The active substance in our lead medicinal product candidate CRD1 is cladribine. The extensive previous experience with cladribine substantially reduces the risk of our developments. Our cladribine product and developments are completely distinct and independent from marketed drug products that contain cladribine as an active substance.

We are convinced that cladribine's demonstrated safety and powerful, well-understood pharmacology can provide benefit in a variety of rare disorders and lead to de-risked treatment innovation.

Chord Therapeutics is run by a small team of experienced professionals. We conduct our drug developments using a well-established virtual biotech business model, outsourcing services to highly specialised vendors. This allows nimble operations and ensures to obtain best quality services in an efficient and cost effective manner.